January 03, 2018
Rose
Boston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding. The round was led by Singapore-based investment company Temasek, with participation from returning investors 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners, as well as new partners Novartis, EDBI, and the Bridge Builder’s Collaborative.
from MobiHealthNews http://ift.tt/2CAhQoy
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment